Vaxil Bio Ltd.
No trades
No trades
Fundamentals and stats
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Vaxil Bio Ltd. is a biotechnology company engaged in the development of signal peptide-based immunotherapies for the treatment of cancer and infectious diseases. Its pipeline consists of ImMucin, SPmAb2, SPmAb6, and MTbuVax. The company was founded on July 26, 2006 and is headquartered in Toronto, Canada.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
VXL has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company